Skip to main content

Selexipag use while Breastfeeding

Medically reviewed by Drugs.com. Last updated on Mar 10, 2025.

Drugs containing Selexipag: Uptravi

Selexipag Levels and Effects while Breastfeeding

Summary of Use during Lactation

No information is available on the use of selexipag during breastfeeding. Because selexipag is more than 99% bound to plasma proteins, the amount in milk is likely to be low. The manufacturer recommends that breastfeeding be discontinued during selexipag therapy. Selexipag and its active metabolite should be completely eliminated from milk in 1 day.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

(Pulmonary Artery Hypertension) Bosentan, Epoprostenol, Nitric Oxide, Sildenafil, Treprostinil

Substance Identification

Substance Name

Selexipag

CAS Registry Number

475086-01-2

Drug Class

Breast Feeding

Lactation

Milk, Human

Antihypertensive Agents

Cardiovascular Agents

Vasodilator Agents

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.